[go: up one dir, main page]

TN2009000450A1 - Derives de pyridine - Google Patents

Derives de pyridine

Info

Publication number
TN2009000450A1
TN2009000450A1 TNP2009000450A TN2009000450A TN2009000450A1 TN 2009000450 A1 TN2009000450 A1 TN 2009000450A1 TN P2009000450 A TNP2009000450 A TN P2009000450A TN 2009000450 A TN2009000450 A TN 2009000450A TN 2009000450 A1 TN2009000450 A1 TN 2009000450A1
Authority
TN
Tunisia
Prior art keywords
pyridine derivatives
compounds
preparation
solvates
pain
Prior art date
Application number
TNP2009000450A
Other languages
English (en)
Inventor
Sharanjeet Kaur Bagal
Karl Richard Gibson
Mark Ian Kemp
Cedric Poinsard
Blanda Luzia STAMMEN
Stephen Martin Denton
Melanie Susanne Glossop
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TN2009000450A1 publication Critical patent/TN2009000450A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés de formule (I) : (I) et leurs sels et produits de solvation pharmaceutiquement acceptables, des procédés pour la préparation des intermédiaires utilisés dans la préparation de et des compositions contenant ces composés et les utilisations de ces composés pour le traitement de la douleur.
TNP2009000450A 2007-05-03 2009-10-29 Derives de pyridine TN2009000450A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91574507P 2007-05-03 2007-05-03
US95753607P 2007-08-23 2007-08-23
PCT/IB2008/001050 WO2008135826A2 (fr) 2007-05-03 2008-04-21 Dérivés de la pyridine

Publications (1)

Publication Number Publication Date
TN2009000450A1 true TN2009000450A1 (fr) 2011-03-31

Family

ID=39855225

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000450A TN2009000450A1 (fr) 2007-05-03 2009-10-29 Derives de pyridine

Country Status (33)

Country Link
US (1) US8134007B2 (fr)
EP (1) EP2183241B1 (fr)
JP (1) JP4657384B2 (fr)
KR (1) KR20100007956A (fr)
CN (1) CN101675040A (fr)
AP (1) AP2516A (fr)
AR (1) AR070636A1 (fr)
AU (1) AU2008247102B2 (fr)
BR (1) BRPI0810202A2 (fr)
CA (1) CA2684105C (fr)
CL (1) CL2008001268A1 (fr)
CO (1) CO6251367A2 (fr)
CR (1) CR11061A (fr)
CU (1) CU23846B1 (fr)
DO (1) DOP2009000254A (fr)
EA (1) EA015952B1 (fr)
EC (1) ECSP099710A (fr)
ES (1) ES2398606T3 (fr)
GE (1) GEP20125379B (fr)
GT (1) GT200900280A (fr)
IL (1) IL201569A0 (fr)
MA (1) MA31419B1 (fr)
MX (1) MX2009011816A (fr)
NI (1) NI200900192A (fr)
NZ (1) NZ581614A (fr)
PA (1) PA8779201A1 (fr)
PE (1) PE20090730A1 (fr)
SV (1) SV2009003400A (fr)
TN (1) TN2009000450A1 (fr)
TW (1) TWI375675B (fr)
UY (1) UY31063A1 (fr)
WO (1) WO2008135826A2 (fr)
ZA (1) ZA200907609B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896942A (zh) 2008-08-06 2014-07-02 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
EA020460B1 (ru) 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
CN101638352B (zh) * 2009-08-14 2011-08-31 大连理工大学 一种芳基取代的氮杂环化合物的制备方法
WO2011077313A1 (fr) 2009-12-22 2011-06-30 Pfizer Inc. Pipéridinecarboxamides en tant qu'inhibiteurs de mpges - 1
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
CN101768036B (zh) * 2010-01-23 2013-05-08 大连理工大学 一种在醇溶剂中制备芳基取代的氮杂芳环化合物的方法
AU2011212928B2 (en) 2010-02-03 2016-06-23 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
CA2788114C (fr) 2010-02-08 2018-11-06 Biomarin Pharmaceutical Inc. Procedes de synthese de derives de dihydropyridophtalazinone
CA2789606A1 (fr) 2010-02-25 2011-09-01 Pfizer Limited Analogues peptidiques en tant qu'agonistes des recepteurs opioides
EP2590951B1 (fr) 2010-07-09 2015-01-07 Pfizer Limited Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
WO2012004714A2 (fr) 2010-07-09 2012-01-12 Pfizer Limited Composés chimiques
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2801032A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
CA2804716A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
WO2012007836A1 (fr) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Composés pyridines comme bloqueurs des canaux sodiques
JP2013543480A (ja) * 2010-10-18 2013-12-05 ラクオリア創薬株式会社 Ｔｔｘ−ｓ遮断薬としてのアリールアミド誘導体
SG189939A1 (en) 2010-10-21 2013-06-28 Biomarin Pharm Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012095781A1 (fr) 2011-01-13 2012-07-19 Pfizer Limited Dérivés d'indazole comme inhibiteurs des canaux sodiques
WO2012120398A1 (fr) 2011-03-04 2012-09-13 Pfizer Limited Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8
EA201391239A1 (ru) 2011-04-05 2014-03-31 Пфайзер Лимитед Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
CA2840317C (fr) 2011-07-13 2016-11-01 Pfizer Limited Analogues d'enkephaline
WO2013054185A1 (fr) 2011-10-13 2013-04-18 Pfizer, Inc. Dérivés de pyrimidine et de pyridine utiles en thérapie
PH12014500919A1 (en) 2011-10-26 2014-06-09 Pfizer Ltd (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
IN2014DN03063A (fr) 2011-10-28 2015-05-15 Inhibitaxin Ltd
WO2013088315A1 (fr) 2011-12-15 2013-06-20 Pfizer Limited Dérivés de sulfonamide
WO2013093688A1 (fr) 2011-12-19 2013-06-27 Pfizer Limited Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
ES2548228T3 (es) 2012-02-03 2015-10-15 Pfizer Inc Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
WO2013136170A1 (fr) 2012-03-16 2013-09-19 Purdue Pharma L.P. Pyridines substituées en tant que bloqueurs des canaux sodiques
RU2632899C2 (ru) * 2012-04-25 2017-10-11 Раквалиа Фарма Инк. Амидопроизводные как блокаторы ttx-s
WO2014053968A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
CA2885247A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinases apparentes a la tropomyosine
CA2887887C (fr) * 2012-10-31 2020-08-25 Raqualia Pharma Inc. Derives de pyrazolopyridine en tant que bloquants de ttx-s
WO2014096941A1 (fr) 2012-12-20 2014-06-26 Purdue Pharma L.P. Sulfonamides cycliques en tant que bloquants des canaux sodiques
EP3865475A1 (fr) * 2013-01-31 2021-08-18 Vertex Pharmaceuticals Incorporated Procédé de préparation d'amides de pyridone qui sont modulateurs de canaux sodiques, et composés intermediaires utilisés dans celui-ci
NZ710111A (en) 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
MX374512B (es) 2013-03-08 2025-03-06 Amgen Inc Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso.
CA2918365C (fr) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfamides utilises comme modulateurs des canaux sodium
BR112016008257A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de roryt de álcool quinolínico secundário
EP3066084A1 (fr) * 2013-11-07 2016-09-14 Medivation Technologies, Inc. Intermédiaires de triazole utiles dans la synthèse de n-alkyltriazolecarbaldéhyde protégés
AP2016009287A0 (en) 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
AU2015315167A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamide compounds
CN106674264A (zh) * 2016-12-20 2017-05-17 苏州汉德创宏生化科技有限公司 (2,2,2‑三氟乙氧基)苯硼酸类化合物的合成方法
CA3063901A1 (fr) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Amides de pyridone deuteres et leurs promedicaments utilises en tant que modulateurs de canaux sodiques
CR20200064A (es) 2017-07-11 2020-08-03 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
CN111163766A (zh) 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
JP7506379B2 (ja) * 2018-02-05 2024-06-26 ユニヴェルスィテ・ドゥ・ストラスブール 疼痛を治療するための化合物および組成物
CA3091012A1 (fr) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated Methode de traitement de la douleur
CN109053434A (zh) * 2018-07-18 2018-12-21 上海华堇生物技术有限责任公司 一种2,4-二甲氧基苯甲酰氯的新制备方法
CN108794328A (zh) * 2018-08-03 2018-11-13 上海华堇生物技术有限责任公司 3,4-二甲氧基苯甲酰氯的制备方法
WO2020146682A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides utilisés en tant que modulateurs de canaux sodiques
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
MX2022001516A (es) * 2019-08-06 2022-03-11 Domain Therapeutics Antagonistas del receptor de neuropeptido ff.
JOP20220130A1 (ar) 2019-12-06 2023-01-30 Vertex Pharma مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN113248455A (zh) * 2021-05-25 2021-08-13 湖北科技学院 一种3,5-二取代异噁唑类衍生物及其合成方法
CA3222197A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Formes galeniques solides et schemas posologiques comprenant du (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
WO2022256622A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
WO2022256676A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Analogues de tétrahydrofurane substitués utiles en tant que modulateurs de canaux sodiques
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
EP4347584A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Analogues de n-(hydroxyalkyl(hétéro)aryl)tétrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
CN115703719B (zh) * 2021-08-03 2024-04-30 联化科技股份有限公司 一种溴化肟类化合物的制备方法
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
WO2025090516A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci
WO2025090465A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
WO2025090480A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2025090511A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527736B1 (fr) * 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Amides d'acide carboxylique-4 d'isoxazol et cyanamides acetiques d'hydroxyalkylidene, medicaments contenant ces composes et leur application
EP0674627A1 (fr) 1992-12-18 1995-10-04 The Wellcome Foundation Limited Derives de pyrimidine, de pyridine, de pteridinone et d'indazole utilises comme inhibiteurs enzymatiques
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
WO1996018617A1 (fr) 1994-12-12 1996-06-20 Merck & Co., Inc. Pyridines 2-acylaminees substitutees utilisees comme inhibiteurs de synthase d'oxyde d'azote
US6011051A (en) 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
DE19857009A1 (de) 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
US6458789B1 (en) 1999-09-29 2002-10-01 Lion Bioscience Ag 2-aminopyridine derivatives and combinatorial libraries thereof
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2411859A1 (fr) * 2000-06-05 2001-12-13 Jae-Gul Lee Nouveaux derives oxazolidinone et processus de preparation de ces derives
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
DE10132308A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
JP2003086564A (ja) * 2001-09-14 2003-03-20 Mitsubishi Electric Corp 遠心乾燥装置および半導体装置の製造方法ならびに半導体製造装置
AU2002363250A1 (en) * 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
PT1474395E (pt) 2002-02-12 2008-01-02 Smithkline Beecham Corp Derivados de nicotinamida úteis como inibidores de p38
WO2004080999A1 (fr) 2003-03-14 2004-09-23 Biolipox Ab Composes de pyrazole utilises dans le traitement de l'inflammation
EP1625115A1 (fr) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Derives pyrimidiques substitues
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
ATE412646T1 (de) 2003-09-22 2008-11-15 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
US20070191363A1 (en) 2004-03-02 2007-08-16 Neurogen Corporation Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues
WO2006011050A2 (fr) * 2004-07-23 2006-02-02 Pfizer Limited Derives de pyridine
US20060106011A1 (en) * 2004-11-12 2006-05-18 Bock Mark G 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
EP1814856A1 (fr) 2004-11-12 2007-08-08 Galapagos N.V. Composés hétéroaromatiques de l'azote qui se lient au site actif d'enzymes de type protéines kinases
CA2620818A1 (fr) 2005-09-02 2007-03-08 Astellas Pharma Inc. Nouveaux composes
US7683056B2 (en) 2005-09-09 2010-03-23 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders
EP1764095A1 (fr) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Nouveaux derivés de nitrocatéchol ayant activité de ligande de selectine
EP1764093A1 (fr) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Nouveaux composés aromatiques et leur application médical
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
TW200732320A (en) 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
KR20080067364A (ko) 2005-10-31 2008-07-18 바이올리폭스 에이비 리폭시게나제 억제제로서의 트리아졸 화합물
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
NZ567892A (en) 2005-11-08 2010-12-24 Vertex Pharma Heterocyclic modulators of ATP-binding cassette transporters containing cycloalkyl or heterocycloalkyl groups
WO2007058990A2 (fr) 2005-11-14 2007-05-24 Kemia, Inc. Therapie a base d’inhibiteurs de cytokine
RU2008126228A (ru) 2005-11-30 2010-01-10 Астеллас Фарма Инк. (Jp) 2-аминобензамидное производное
WO2007083239A1 (fr) 2006-01-23 2007-07-26 Pfizer Limited Dérivés de pyridine en tant que modulateurs du canal sodium
CA2639927A1 (fr) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Composes biaryle substitues destines a des utilisations contre des inflammations et des troubles immunitaires
US20070254926A1 (en) 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
BRPI0707945A2 (pt) 2006-02-17 2011-05-17 Pfizer Ltd derivados de 3-deazapurina como modulares de tlr7
EP2004607B1 (fr) 2006-03-31 2011-10-19 Novartis AG Dérivés de l'acide (4-(4-[6-(trifluorométhyl-pyridin-3-ylamino)-N-contenant-hétéroaryl]-phényl)-cyclohexyl)-acétique et leurs applications pharmaceutiques
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US7795249B2 (en) 2006-12-22 2010-09-14 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
AU2008205252B2 (en) 2007-01-09 2013-02-21 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
EP2132177B1 (fr) 2007-03-01 2013-07-17 Novartis AG Inhibiteurs de pim kinase et procédés de leur utilisation
EP2155727A1 (fr) 2007-05-03 2010-02-24 Pfizer Limited Dérivés n-[6-amino-5-(phényl)pyrazin-2-yl]-isoxazole-4-carboxamide et composés similaires en tant que modulateurs du canal nav1.8 pour le traitement de la douleur

Also Published As

Publication number Publication date
PA8779201A1 (es) 2009-01-23
AR070636A1 (es) 2010-04-28
TW200906403A (en) 2009-02-16
SV2009003400A (es) 2010-08-17
ZA200907609B (en) 2011-04-28
AU2008247102B2 (en) 2011-11-24
WO2008135826A3 (fr) 2009-02-05
CR11061A (es) 2009-11-03
CO6251367A2 (es) 2011-02-21
BRPI0810202A2 (pt) 2014-10-21
AP2516A (en) 2012-11-26
JP2010526050A (ja) 2010-07-29
EP2183241A2 (fr) 2010-05-12
EA200970913A1 (ru) 2010-04-30
ECSP099710A (es) 2009-11-30
CU23846B1 (es) 2012-10-15
CL2008001268A1 (es) 2008-11-03
US8134007B2 (en) 2012-03-13
MX2009011816A (es) 2009-11-19
EP2183241B1 (fr) 2012-12-19
JP4657384B2 (ja) 2011-03-23
TWI375675B (en) 2012-11-01
GEP20125379B (en) 2012-01-10
CN101675040A (zh) 2010-03-17
UY31063A1 (es) 2009-01-05
GT200900280A (es) 2011-08-29
CU20090180A7 (es) 2011-05-27
US20090048306A1 (en) 2009-02-19
MA31419B1 (fr) 2010-06-01
AP2009005009A0 (en) 2009-10-31
EA015952B1 (ru) 2011-12-30
WO2008135826A2 (fr) 2008-11-13
CA2684105C (fr) 2011-09-06
KR20100007956A (ko) 2010-01-22
CA2684105A1 (fr) 2008-11-13
PE20090730A1 (es) 2009-07-11
IL201569A0 (en) 2010-05-31
AU2008247102A1 (en) 2008-11-13
ES2398606T3 (es) 2013-03-20
NI200900192A (es) 2010-07-15
NZ581614A (en) 2011-06-30
DOP2009000254A (es) 2009-11-30

Similar Documents

Publication Publication Date Title
TN2009000450A1 (fr) Derives de pyridine
TNSN07022A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2011000316A1 (fr) Derives de sulfonamides
MA29791B1 (fr) Composes therapeutiques.
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA31754B1 (fr) Cis-imidazolines chirales
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA31766B1 (fr) Composés organiques
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA31894B1 (fr) Composes organiques
MA38138A1 (fr) Dérivés inédits de quinolone
EP2571876A4 (fr) Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
MA31683B1 (fr) Composes et procedes pour moduler fxr